FDA approves diabetes drug with new approach

Published on NewsOK Modified: January 8, 2014 at 12:01 pm •  Published: January 8, 2014
Advertisement
;

WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a new diabetes drug from Bristol-Myers Squibb and AstraZeneca that uses a novel approach to reduce blood sugar.

Farxiga is a once-a-day tablet designed to help diabetes patients eliminate excess sugar via their urine. That differs from older drugs that decrease the amount of sugar absorbed from food and stored in the liver.

The drug is the second product approved in the U.S. from the new class of medicines known as SGLT2 drugs. In March the FDA approved Johnson & Johnson's Invokana, which also works by eliminating excess sugar through patients' urine.

The agency cleared Farxiga tablets for patients with type 2 diabetes, which affects about 24 million people in the U.S. The approval marks a comeback for the drug, which was previously rejected last year after studies raised concerns about links to bladder cancer and liver toxicity.

Ten cases of bladder cancer were found in patients taking the drug in clinical trials, so Farxiga's label warns against using it in patients with the disease. A panel of FDA advisers last month said that the uptick in cancers was likely a statistical fluke, and not related to the drug. But the FDA is requiring Bristol and AstraZeneca to track rates of bladder cancer in patients enrolled in a long-term follow up study. The companies will also monitor rates of heart disease, a frequent safety issue with newer diabetes medications.



Trending Now


AROUND THE WEB

  1. 1
    Did Pope Francis really tell a 90-year-old atheist journalist that 1 in 50 priests are pedophiles?
  2. 2
    Facebook and Twitter won the World Cup Final
  3. 3
    Dead body falls out of coroner's van along busy road
  4. 4
    Tracy Morgan: Recovering in style -- first pic since NJ turnpike crash
  5. 5
    Ex-captive Sgt. Bowe Bergdahl could return to active duty Monday
+ show more